You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Therapy Areas: Oncology
Aro Biotherapeutics Names Cancer Biologist McMahon and Protein Structure and Design Expert Swanson to its Scientific Advisory Board
Login
Username:

Password:


Related Headlines

AstraZeneca reports survival gains in Phase III bladder cancer trial

Creatv Bio opens CLIA-certified laboratory in Monmouth Junction, NJ

SOPHiA GENETICS and Synnovis partner to expand NHS liquid biopsy testing

AngioDynamics reports 24-month PRESERVE data showing durable NanoKnife outcomes in prostate cancer

Kelun-Biotech's SKB118 PD-1 x VEGF bispecific antibody receives Chinese regulatory Investigational New Drug approval

Servier's Emi-Le receives US FDA breakthrough therapy designation for adenoid cystic carcinoma

Ranok Therapeutics reports positive Phase 1a clinical results for KRAS G12D inhibitor RNK08954

Hengrui Pharma and Bristol Myers Squibb agree to jointly advance oncology, haematology and immunology medicines

Anixa Biosciences reports extended survival signals in Phase 1 ovarian cancer CAR-T trial

Poolbeg Pharma secures Canadian patent grant for POLB 001

Harbour BioMed's HBM7004 receives US FDA IND clearance for Phase I trial

Innovent's IBI363 receives third Chinese regulatory BTD for MSS/pMMR CRC

Rznomics receives FDA RMAT designation for HCC candidate RZ‑001

Halozyme and GSK sign global drug‑delivery collaboration

Partner Therapeutics' BIZENGRI receives FDA Commissioner's National Priority Voucher for NRG1 fusion-positive cholangiocarcinoma

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026